Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With PrEP Adherence and Support Services
Yale University
526 participants
Oct 4, 2021
INTERVENTIONAL
Conditions
Summary
The proposed study will be a 24-week intervention with a 12-month follow-up period to evaluate the impact of contingency management with stepped care to pre-exposure prophylaxis (PrEP) adherence and support services (CoMPASS) to promote HIV prevention among individuals with opioid use disorder who have injected drugs in their lifetime. In parallel, the investigators will conduct an implementation focused process evaluation to inform real-world implementation of CoMPASS. .
Eligibility
Inclusion Criteria11
- Aims 1 and 2:
- Receive or willing to receive care at one of the participating study sites
- Have a recent negative HIV test with no concern for acute HIV
- Report injection drug use in their lifetime
- Meet PrEP eligibility criteria by either a) sharing of injection or drug preparation equipment; b) sexual risk behaviors (i.e. condomless sex or STI) in the past 6 months
- Meet Diagnostic and Statistical Manual of Mental Disorders - 5th edition (DSM5) criteria for opioid use disorder
- Have a phone or use of a household member's phone
- Provide written informed consent
- Aim 3:
- Currently employed at one of the participating study sites
- Willing to complete a web-based survey
Exclusion Criteria9
- Aims 1 and 2:
- Currently prescribed PrEP
- Self-report or urine test confirming pregnancy, breastfeeding, or trying to conceive
- Any plans that would preclude study completion (surgery, major medical treatment or conditions, incarceration, travel out of state or country.)
- Inability to provide at least one collateral contact for a friend or family member.
- Non-English speaking (for sites without Spanish-speaking staff)
- Have kidney disease (a contraindication to PrEP)
- Aim 3:
- \. Non-English speaking
Interventions
Participants will receive contingency management sessions (n=9). Participants who do not demonstrate PrEP adherence by week 12 will be "stepped up" to receive PrEP adherence and support services (n=5).
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04738825